Pharmacokinetic Study of Belviq in Adult Korean Volunteers
Completed
IlDong Pharmaceutical Co Ltd
Phase 1
2013-06-01
A randomized, double-blind, placebo-controlled, single-dose, dose escalation study (Phase I)
to evaluate the tolerability and pharmacokinetics of Belviq in adult Korean volunteers.
Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study
Unknown status
Southern California Institute for Research and Education
Phase 4
2014-01-01
The purpose of this study is to determine whether lorcaserin is effective for weight
reduction in patients with weight gain as a result of antipsychotic medications.
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Mul
Completed
Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization
Phase 4
2014-01-24
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in
overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk
factors.
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Mul
Completed
Eisai Inc.
Phase 4
2014-01-24
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in
overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk
factors.
Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age
Completed
Arena Pharmaceuticals
Phase 1
2013-12-01
The purpose of this study is to evaluate the PK properties, tolerability, and safety of
lorcaserin HCL (BELVIQ) in obese adolescent subjects between the ages of 12 to 17 years old
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.